| ²é¿´: 1029 | »Ø¸´: 5 | ||
mollyzhangÌú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖúרÀû²éѯ£¡
|
|
[ÇóÖú]ÇóÖú¹ØÓÚרÀû²éѯµÄÒ»¸öÎÊÌâ! ³õʼÐüÉͽð±Ò 50 ¸ö ×î½ü×÷¹ØÓÚÒ»¸ö°ÐµãµÄÎÄÏ×µ÷ÑÐ, ²éÁ˼¸¼Ò¹«Ë¾£¬ ÈçPamlico Pharmaceutical Inc£¬Axxam£¬Advinus Therapeutics,ÔÚÆä¹«Ë¾Ö÷Ò³ÉÏÓйØÓÚGPR120µÄÐÅÏ¢,µ«ÊÇÎÞÂÛ²éscifinder,»¹ÊÇderwent£¬»¹ÊÇÔÚÅ·ÖÞרÀû¾ÖºÍÃÀ¹úרÀû¾Ö¶¼Ã»ÓÐÕÒµ½¸Ã¹«Ë¾¸Ã°ÐµãµÄרÀû¡£ÏëÇë½Ìר¼ÒÊÇûÓÐÉêÇëרÀû£¿»¹ÊÇûÓй«¿ª£¿¡¡ ÔÚÌÀÄ·Ñ·Öв鵽µÄÐÅÏ¢ Pamlico Pharmaceutical is investigating a G-protein coupled receptor 120 (GPR120) agonist for the potential treatment of diabetes. In September 2011, the program was in lead optimization [1226961]; in March 2013, this was still the case [1390000]. In September 2011, the company was seeking to outlicense its programs [1226961]. ÔÚ£²£°£±£±Äê¸Ã¹«Ë¾¾ÍÔÚoutlicense its programs£¬ÄÇÓ¦¸ÃÓÐרÀûÁ˰ɣ¿¡¡ÎªÊ²Ã´²é²»µ½ÄØ£¿ ¸Ã¹«Ë¾ÍøÕ¾ http://www.pamlicopharma.com/Home/research »¹ÓÐAxxam¡¡ http://www.axxam.com/discoverypro/discpro.asp Advinus Therapeutics http://www.advinus.com/pipeline.asp ÔÚÌÀÄ·Ñ·Öв鵽µÄÐÅÏ¢ Advinus Therapeutics is investigating dual agonists of GPR40 and GPR120, for the potential treatment of type 2 diabetes [1231883], [1488118]. In October 2011, the program was in discovery and target identification was underway [1231883]; in October 2013, the program was listed as being under hit-to-lead development [1488118]. In October 2011, the company was seeking to outlicense the programs [1231883]. ÒÔÉϼ¸¼Ò¹«Ë¾¶¼²é²»µ½Æä¸Ã°ÐµãµÄרÀû£¬Çóר¼Ò½â»ó£¡²»Ê¤¸Ð¼¤£¡ |
» ²ÂÄãϲ»¶
285Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ19È˻ظ´
277¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
277Çóµ÷¼Á ÊýÒ»104·Ö
ÒѾÓÐ13È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
336Çóµ÷¼Á£¬Ò»Ö¾Ô¸Öпƴó
ÒѾÓÐ6È˻ظ´
071000ÉúÎïѧ£¬Ò»Ö¾Ô¸ÉîÛÚ´óѧ296·Ö£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ19È˻ظ´
274Çóµ÷¼ÁÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÈçºÎ¼ìË÷ÖÆ¼ÁרÀû£¬Ð»Ð»£¡
ÒѾÓÐ5È˻ظ´
ÇóÖúp-t-kͼÔÚÄĶù²é°¡¡£¡£¡£
ÒѾÓÐ3È˻ظ´
ÈçºÎ²éѯij¸öÒ©ÎïרÀû±£»¤µ½ÆÚʱ¼ä
ÒѾÓÐ7È˻ظ´
ÈçºÎ²éÕÒÌØ¶¨Ê±¼ä¶ÎרÀû¹ýÆÚÒ©Æ·
ÒѾÓÐ8È˻ظ´
ÈçºÎ²éѯҩÎïËùÓÐÉæ¼°×¨Àû£¿°üÀ¨»¯ºÏÎïרÀû¡¢ÖƱ¸·½·¨×¨ÀûµÈ£¿
ÒѾÓÐ10È˻ظ´
ÈçºÎ²éѯһ¸öÒ©ÊÇ·ñרÀûµ½ÆÚ¡¢¼°ÆäÔÑÐÇé¿ö
ÒѾÓÐ16È˻ظ´
°¢Äá·Ò¾»µÄרÀûÇóÖú
ÒѾÓÐ12È˻ظ´
ÇóÖú²éѯרÀûµÄÓÅÐãÍøÕ¾
ÒѾÓÐ8È˻ظ´
¹ú¼ÊרÀûÊÇ·ñÔÚÖйúÉêÇëÈçºÎ²éѯ£¿
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú¡¿²éѯ³É¶¼Äܼû¶È
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿Õæ³ÏÇóÖúÒ©Æ·»¯ºÏÎïÔʼרÀûÔõô²éÕÒ£¿
ÒѾÓÐ50È˻ظ´
¹úÍâרÀû²éѯÎÊÌ⣨ÇóÖú£©
ÒѾÓÐ6È˻ظ´
ÇóÖúÔõôÑù²éרÀûµÄÐÅÏ¢
ÒѾÓÐ1È˻ظ´
¡¾ÇóÖú¡¿Çë½ÌÅ·ÖÞרÀûÏÂÔØµÄÎÊÌâ
ÒѾÓÐ16È˻ظ´
¡¾ÇóÖú¡¿ÇëÎÊÒ»°ãÔÚÄĸöÊý¾Ý¿â²éרÀûÈ«ÎÄ
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿×¨Àû²éѯµÄÎÊÌâ
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿ÇóÎÊÔõô²éij¸öÒ©ÎïרÀûÊÇ·ñµ½ÆÚ£¿
ÒѾÓÐ18È˻ظ´
wsh14
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 46 (СѧÉú)
- ½ð±Ò: 6959.9
- ºì»¨: 32
- Ìû×Ó: 482
- ÔÚÏß: 1630.6Сʱ
- ³æºÅ: 1094781
- ×¢²á: 2010-09-10
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
2Â¥2013-11-10 19:21:06
yangzihui
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
µ¥ÝÆÀàɱ¾ú¼Á
- Ó¦Öú: 31 (СѧÉú)
- ½ð±Ò: 10416.6
- É¢½ð: 474
- ºì»¨: 3
- Ìû×Ó: 1253
- ÔÚÏß: 362.9Сʱ
- ³æºÅ: 1269717
- ×¢²á: 2011-04-18
- ÐÔ±ð: GG
- רҵ: ÌìȻҩÎﻯѧ

3Â¥2013-11-10 22:09:44
wsh14
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 46 (СѧÉú)
- ½ð±Ò: 6959.9
- ºì»¨: 32
- Ìû×Ó: 482
- ÔÚÏß: 1630.6Сʱ
- ³æºÅ: 1094781
- ×¢²á: 2010-09-10
- ÐÔ±ð: GG
- רҵ: Ò©¼Áѧ
4Â¥2013-11-10 23:48:25
mollyzhang
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 13 (СѧÉú)
- ½ð±Ò: 10274.1
- É¢½ð: 350
- ºì»¨: 4
- Ìû×Ó: 2490
- ÔÚÏß: 417.4Сʱ
- ³æºÅ: 53071
- ×¢²á: 2004-09-12
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
5Â¥2013-11-11 15:34:04
yangzihui
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
µ¥ÝÆÀàɱ¾ú¼Á
- Ó¦Öú: 31 (СѧÉú)
- ½ð±Ò: 10416.6
- É¢½ð: 474
- ºì»¨: 3
- Ìû×Ó: 1253
- ÔÚÏß: 362.9Сʱ
- ³æºÅ: 1269717
- ×¢²á: 2011-04-18
- ÐÔ±ð: GG
- רҵ: ÌìȻҩÎﻯѧ

6Â¥2013-11-12 18:54:36














»Ø¸´´ËÂ¥
´ËÓ¦¸Ãµ½drugnatureÉÏËÑË÷£¬ÊäÈëרÀûºÅ¼´¿É¡£